Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.

@article{Andonov2013PretreatmentRT,
  title={Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.},
  author={Anton Andonov and Kamran Kadkhoda and Carla Osiowy and Kelly D E Kaita},
  journal={Canadian journal of gastroenterology = Journal canadien de gastroenterologie},
  year={2013},
  volume={27 7},
  pages={414-6}
}
BACKGROUND Traditional therapy with pegylated interferon and ribavirin combined with the new protease inhibitors boceprevir or telaprevir has demonstrated improved outcomes in hepatitis C virus (HCV)-infected patients. Prevalence data regarding pre-existing drug-resistant variants to these two new virus inhibitors in the Canadian population are not available. OBJECTIVE To detect pre-existing mutations conferring resistance to boceprevir and⁄or telaprevir in Canadian patients infected with HCV… CONTINUE READING